Results 11 to 20 of about 13,569 (208)

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio [PDF]

BMC Cardiovascular Disorders, 2006
Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the question of ...
Baur Regine, Müller Lutz von, Alan Mustafa, Voisard Rainer, Hombach Vinzenz   +4 more
doaj   +3 more sources

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives

Therapeutics and Clinical Risk Management, 2014
Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj   +2 more sources

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells [PDF]

Cardiovascular Diabetology, 2008
Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua, Zhao Renyi, Pathak Alokkumar, Stouffer George A   +3 more
doaj   +3 more sources

Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. [PDF]

Transfusion
Abstract Background Cryoprecipitate Anti‐Haemophilic Factor (CRYO‐AHF) is enriched for fibrinogen, VWF, FVIII, FXIII and fibronectin, but has short post‐thaw expiration due to risk of transfusion‐transmitted infection (TTI) limiting availability for rapid treatment.
Tupin F, Mouriaux C, Gatmaitan M, Kaastrup K, Yegneswaran S, Corash L, Mangin PH.   +6 more
europepmc   +2 more sources

Pathogen-reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange. [PDF]

Transfusion
Abstract Background Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto‐immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion‐transmitted infection (TTI).
Tupin F, Mouriaux C, Hechler B, Kaastrup K, Yegneswaran S, Corash L, Mangin PH.   +6 more
europepmc   +2 more sources

Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine. [PDF]

Catheter Cardiovasc Interv
ABSTRACT The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI).
Howes S, Altaee O, Ramirez A, Calaquian L, Asif A, Stone C, Hammadah M, Roy D, Ramsey B, Chilton R.   +9 more
europepmc   +2 more sources

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Variable selection is essential for propensity score (PS)‐weighted estimators. Recent work shows that including instrumental variables (IVs), associated with only treatment but not with the outcome, can impact both the bias and precision of the PS‐weighted estimators.
Choi BY, Brookhart MA.
europepmc   +2 more sources

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper. [PDF]

Allergy
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Cortellini G, Nakonechna A, Barbaud A, Bavbek S, Calogiuri G, Doña I, Kvedariene V, Laguna Martinez JJ, Liberati S, Pagani M, Romano A.   +10 more
europepmc   +2 more sources

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]

, 2017
Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat, Applegate, Richard, Araujo, Camila, Ho, Wing Mann, Huang, Lei, Reis, Cesar, Zhang, John H   +6 more
core   +8 more sources

Quantitative structural mechanobiology of platelet-driven blood clot contraction. [PDF]

, 2017
Blood clot contraction plays an important role in prevention of bleeding and in thrombotic disorders. Here, we unveil and quantify the structural mechanisms of clot contraction at the level of single platelets.
Alber, Mark S, Kim, Oleg V, Litvinov, Rustem I, Weisel, John W   +3 more
core   +2 more sources